: iStockAnalyst.com Symbols Feed

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

Tue, 20 Oct 2009 02:19:35 GMT

At the beginning of the month, Celldex Therapeutics (NASDAQ: CLDX) announced the successful completion of its acquisition of CuraGen (formerly CRGN), which strengthens the balance sheet (approx. $85 million in cash / equivalents) while expanding the pipeline and increasing the expected news flow of clinical data catalysts for the combined entity[More...]

Our Outlook for Health-Care Stocks

Thu, 01 Oct 2009 22:55:00 GMT

The key development on the health-care reform front occurred just before the end of the third quarter. The long-anticipated proposal from the Senate Finance Committee finally materialized and, as is typical of any proposal that attempts to take a centrist approach, was greeted with a barrage of criticism from both ends of the political spectrum.[More...]

Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities

Tue, 29 Sep 2009 19:31:31 GMT

Access Pharma (OTC: ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).[More...]

Partnerships And Mergers Updates : Wipro Partners with BP, Endo Buys US Rights to Fortesta, Siemens Buys China Metal, Google's Search for Italian Solution

Fri, 28 Aug 2009 18:10:58 GMT

Wipro Technologies, the IT services business of Wipro Ltd. (WIT) announced that it has entered into a five year agreement with BP Plc. (BP) to provide IT Applications Development and Maintenance services for BP’s Fuels Value Chain and Corporate businesses across the globe. Endo Pharmaceuticals (ENDP) signed an agreement with UK-based ProStrakan Group Plc to acquire exclusive rights to commercialize Fortesta in the U.S., where the product is currently under Food and Drug Administration (FDA) review. Siemens Energy, a division of Siemens AG (SI), acquired the majority holding in the Chinese metalworking company Yangtze Delta Manufacturing and the Chinese aluminum foundry GISAP (GIS Steel & Aluminium Products), both headquartered in Hangzhou. The Italian Federation of Newspaper Publishers recently filed an anti-trust complaint against Google Inc. (GOOG). This prompted the Italian Competition Authority to search Google’s Milan offices on Thursday, pursuant to a probe that was ini[More...]

The Big Picture on the Biotech Rally - NBI

Fri, 07 Aug 2009 19:30:08 GMT

Biotech bulls have come out of hiding... The S and P 500 has been on fire since May, up 9% in the last month alone. But the Nasdaq Biotechnology Index (NBI) – a proxy for the biotech industry – has spanked stocks in general by an additional 10%. The Growth Stock Wire $NBI http://www.growthstockwire.com/images/charts/2009/aug/20090807_chart_a.gif http://www.growthstockwire.com/ Biotech investors have enjoyed this amazing run for three reasons... Buyouts: 2009 is shaping up to be a stellar year for investment bankers. We've seen over 40 significant merger and acquisition deals in health care, well ahead of the normal pace. And the acquisition premiums have been astounding... Just two weeks[More...]

Is It The Right Time To Buy Biotechnology Investments?

Thu, 30 Jul 2009 19:39:43 GMT

Share prices in the biotech sector have seen strong gains in recent weeks and it is logical to ask if it is too late to get on the biotech bandwagon. The answer, generally speaking, is no as long as investors get a few things right.[More...]

Catch These Stocks And You'll Never Have To Work Again

Wed, 29 Jul 2009 15:52:16 GMT

There's no fever like gold fever... unless you're in a biotech bull market. Since 1980, the Datastream Biotech Index has enjoyed four separate triple-digit rallies... including a 646% moonshot in the late 1990s and a 421% blast in the mid-1980s. In the early 1990s, the index rose 1,347% in less than four years. We crunched the numbers on biotech bull markets and found the average gain in a biotech bull market is 565% over 2.6 years. There's just no other group of stocks that rally like biotechs. As we've said in DailyWealth before, if you catch just one biotech bull market, you'll never have to work again... The last major biotech bull market topped in 2000, along with technology stocks. They've been dogs since then. On March 6, 2000, the Nasdaq Biotech Index was around 1,600. Today, it's around 800 – still down 50% from its peak more than[More...]

Bristol-Myers Squibb Company (BMY) Announces Merger with Medarex, Inc.

Thu, 23 Jul 2009 17:36:17 GMT

Bristol-Myers Squibb Company and Medarex, Inc. (NASDAQ: MEDX) were excited to announce that the companies have signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb for $16.00 per share in cash. Both companies’ boards of directors have unanimously approved the transaction, with an aggregate purchase price of approximately $2.4 billion. Medarex’s projected $300 million in net cash and marketable securities at closing would be an asset acquired by Bristol-Myers Squibb resulting in an implied purchase price of approximately $2.1 billion. James M. Cornelius, chairman and chief executive officer of Bristol-Myers Squibb, stated, “Medarex’s technology platform, people and pipeline provide a strong complement to our company’s biologics strategy, specifically in immuno-oncology. With its productive and proven antibody discovery capabilities, ability to generate interesting therapeutic programs and unique set of[More...]

BMY Sees Growth; Acquires MEDX

Thu, 23 Jul 2009 15:21:26 GMT

Bristol-Myers (BMY) reported second-quarter total revenues of $5,384 million this morning, an increase of 4% from the second quarter in 2008. This was ahead of our forecasts by $125 million. Revenues consisted of $4,665 million in pharmaceutical product sales, up 9%, and $719 million in Nutritional sales, down 1%. Growth in the pharmaceutical division was driven by strong sales of Plavix at $1,539 million, up 11%, Sustiva at $312 million, up 11%, Baraclude at $179 million, up 32%, Abilify at $643 million, up 22%, Orencia at $148 million, up 40%, and Sprycel at $109 million, up 43%. Adjusted (non-GAAP) net income for the second quarter totaled $1,103 million, up 28% from the second quarter in 2008. This equated to earnings per share of 56 cents, up 29% and 10 cents above our forecast. GAAP net income,[More...]

Stocks Of The Day: Medarex (NASDAQ: MEDX); AK Steel (NYSE: AKS)

Tue, 23 Jun 2009 16:44:57 GMT

Medarex Inc., a biopharmaceutical company, discovers, develops, and commercializes human antibody-based therapeutic products to treat cancer, inflammation, autoimmune disorders, as well as other life-threatening and debilitating diseases.[More...]

Dow tops 9,000 as home sales rise for 3rd month

Thu, 23 Jul 2009 22:49:00 GMT

NEW YORK - Investors celebrated news of another jump in home sales by propelling the Dow Jones industrials to their first close above 9,000 since January.
The stock market's best-known indicator shot up almost 190 points Thursday to 9,069.29, its highest level since November, and all the big indexes gained more than 2 percent.
News that existing home sales rose in June for the third straight month and by a higher-than-expected amount led investors to extend a buying spree that has now lifted the Dow 923 points, or 11 percent, in just nine days.

: iStockAnalyst.com Symbols Feed

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

Our Outlook for Health-Care Stocks

Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities

Partnerships And Mergers Updates : Wipro Partners with BP, Endo Buys US Rights to Fortesta, Siemens Buys China Metal, Google's Search for Italian Solution

The Big Picture on the Biotech Rally - NBI

Is It The Right Time To Buy Biotechnology Investments?

Catch These Stocks And You'll Never Have To Work Again

Bristol-Myers Squibb Company (BMY) Announces Merger with Medarex, Inc.

BMY Sees Growth; Acquires MEDX

Stocks Of The Day: Medarex (NASDAQ: MEDX); AK Steel (NYSE: AKS)

Dow tops 9,000 as home sales rise for 3rd month

Ford, Safeway, EMC, Fifth Third are big movers

Strong sales boost Bristol-Myers 2Q profit

Bristol-Myers, Wyeth turn in strong 2Q results

Strong sales boost Bristol-Myers 2Q profit

Stock futures hold on to gains after labor data

Strong sales boost Bristol-Myers 2Q profit

Stock futures push higher amid earnings, jobs data

Stocks hold steady amid latest earnings

Strong sales boost Bristol-Myers 2Q profit

Bristol-Myers Squibb Completes Acquisition of Medarex, Inc.

Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. With 87.7% of Shares Tendered; Announces Subsequent Offering Period

Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc.

BenchmarkJournal.Com Free Analyst Review for KERX, MEDX, AMCC, HBAN, JBLU and LNCR

Brower Piven Announces the Filing of Class Action Lawsuit Against Medarex, Inc.

Harwood Feffer LLP Files Class Action On Behalf of Shareholders of Medarex, Inc. -- MEDX

Medarex Announces 2009 Second Quarter Financial Results

Bristol-Myers Squibb Begins Tender Offer to Acquire Medarex, Inc.

Fitch Expects Bristol-Myers Squibb's Ratings to Be Unaffected By Medarex Acquisition

Bristol-Myers Squibb to Acquire Medarex

Form 4 NICHOL GEOFFREY For: Sep 01 (10K)

Form 4 SCHADE CHRISTIAN S For: Sep 01 (10K)

Form 4 PEPIN RONALD For: Sep 01 (10K)

Form 4 LONBERG NILS For: Sep 01 (10K)

Form 4 Dietl Deanna For: Sep 01 (10K)

Form 4 Bartels Ursula B For: Sep 01 (10K)

Form 4 PIEN HOWARD H For: Sep 01 (10K)

Form 4 VIDA JULIUS A For: Sep 01 (10K)

Form 4 SCHALLER CHARLES R For: Sep 01 (10K)

Form 4 SALDARINI RONALD J For: Sep 01 (10K)